Aquestive Therapeutics (AQST) Total Current Liabilities (2017 - 2026)

Aquestive Therapeutics' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $31.8 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 73.53% year-over-year to $31.8 million in Q1 2026; TTM through Mar 2026 was $31.8 million, a 73.53% increase from a year earlier, with the FY2025 full-year figure at $47.6 million, up 152.36% from the prior year.
• Total Current Liabilities retreated to $31.8 million in Q1 2026 per AQST's latest filing, from $47.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $47.6 million in Q4 2025 and bottomed at $13.9 million in Q2 2024.
• The 5-year median for Total Current Liabilities is $24.2 million (2022), against an average of $27.3 million.
• Across the five-year window, Total Current Liabilities plunged 64.05% in 2024 and soared 152.36% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $39.5 million in 2022, then plunged by 53.68% to $18.3 million in 2023, then increased by 3.04% to $18.9 million in 2024, then surged by 152.36% to $47.6 million in 2025, then slumped by 33.3% to $31.8 million in 2026.
• Per Business Quant, the three latest AQST Total Current Liabilities figures stand at $31.8 million (Q1 2026), $47.6 million (Q4 2025), and $25.6 million (Q3 2025).